Deal Pipeline

Deal Pipeline

Reference Summary Focus Country Raising Stage
1 A Biomed company aiming to leverage proprietary computational systems including AI to accelerate development of novel drug alternatives to life threatening diseases like cancer, bacterial infections and muscular dystrophy. AI & Drug Development USA $20m IND
2 A Biomed company providing specialised rehabilitation services to treat patients suffering from drug addiction and opioid dependence with clinics using therapies from a specialised drug. The company is focused on creating a diverse real estate portfolio with healthcare and detox related assets whose sole purpose are to establish turn-key addiction recovery facilities. Addiction Canada $5m Pre revenue
3 A Biomed company that is developing a novel therapeutic class of medicines that use the body's natural immune response to decrease inflammation and stimulate repair mechanisms, thereby repairing the damage caused by disease and slowing aging. Aging USA $50m Phase 3
4 A Biomed company in its commercial stages with products designed to empower people to stay younger longer with DNA analysing technology that helps patients understand their telomere length and better care for their cells with the provided knowledge, encouragement and goal setting. Aging USA $15-20m Commercial stage
5 A Biotech company with a mission to apply AI technology to accelerate drug discovery in order to make the process quicker and more cost-efficient. AI & Drug Development China $10m Pre-A
6 A Biopharmaceutical company developing new drugs faster and cheaper with lower risk based on biological big data-based and AI-driven drug development. AI & Drug Development USA $6.5m Revenue generating & early hit to lead stage
7 A Pharmaceuticals company developing and commercializing anti-inflammatory therapeutics, with the company’s lead program around the proprietary target molecule TIRC7, promising a significant leap in the treatment of autoimmune diseases and transplanted organ rejection Anti-inflammatory Therapeutics USA $15m Preclinical
8 A Biopharmaceutical company developing a pro-resolving drug focused on treating Cystic Fibrosis through anti-inflammatory mechanisms involving docosahexaenoic acid, terminating inflammation without inducing immune suppression.. Anti-inflammatory Therapeutics Canada $4m Phase 2
9 A Biomed company that is developing the first specific treatment for anti-phospholipid syndrome, to help prevent thrombus formation and fetal loss in patients suffering from the disease. Antiphospholipid Syndrome Norway $2.6m Preclinical
10 A Medical Software company that has built an enterprise software platform that links biological design with automation, testing and machine learning with examples of use being multi-year crop protection biomolecule design/build/test project. Biology Software USA $8m Revenue generating
11 A Biotech company focused on the development of a phase 3 angiogenic gene therapy product candidate for the treatment of refractory angina and cardiac syndrome X, among other indications. Cardiovascular USA $5m Phase 3
12 A Medical Device company that is producing an ECMO (extra corporeal membrane oxygenation) machine which is easily transportable and designed to provide better outcomes for patients and less time in the intensive care unit. Cardiovascular Canada $5m Awaiting FDA approval
13 A Biotech company that has developed a nano-therapeutic delivery system containing conjugated rapamycin that can target unseen, unstable cardiovascular atherosclerotic plaques directly at the source of the problem. Cardiovascular USA $5.67m Pre-IND
14 A revenue generating Medical Device company producing the latest treatment option using radiofrequency ablation (laser), to treat patients with venous disease and varicose veins/swelling/aching legs/lower limb ulcers. Cardiovascular (Venous Disease) USA $10-$12m Revenue generating
15 A Biomed company producing antiplatelet therapy for Clopidogrel-resistant heart attack and stroke patients which has more efficacy and less bleeding risk. Cardiovascular and Metabolic USA $8m Phase 1
16 A Product Development company focused on biomaterial innovations for the dental market, seeking to commercialise the dental product portfolio for socket extractions, implant packing, ridge augmentation and sinus lift. Dentistry USA $5.5m Preclinical
17 A Biotech company focused on altering the delivery pathways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. Drug Delivery USA $1-2m Currently licensing
18 A Biotech company developing a wireless remote controlled drug delivery system, providing effective and targeted drug delivery via an ingestible capsule. Drug Delivery USA $3m Preclinical
19 A Drug Development company currently developing three promising drugs including radioprotection drugs for prevention of oral mucositis in head and neck cancer currently in phase 2, IBS-D drugs with phase 2a complete and nocturia drugs also with phase 2a complete. Drug Development USA $40m Phase 2
20 A Biopharmaceutical company focused on high-end generics and 505b2 new drugs currently building a portfolio of drugs to commercialise. Drug Development China $20m Revenue generating
21 A Biopharmaceutical company with orphan drug focus and two initial product candidates based on Carmeseal, one daily subcutaneous dosing similar to insulin and another formulation for acute decompensated heart failure. Drug Development USA $2m Phase 2
22 A Biopharmaceutical company focused on a completely new direction in the development of medicines for inflammatory diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases and aging-related diseases. Drug Development USA $30-$50m Phase 2/3
23 A Biopharmaceutical company that develops pharmaceutical products to reduce or eliminate the undesirable side effects of marketed drugs and make certain drugs effective in patients who do not currently benefit from therapy, labelling them as so called 'companion' drugs. Drug Development USA $5.1m Phase 1/2
24 A Biopharmaceutical company focused on producing a platform of drugs with potentially significant long-term clinical benefits that treat a wide range of respiratory and autoimmune diseases and cancer. Drug Development USA $20m Phase 2
25 A Growth-Oriented CDMO company providing comprehensive services of drug development and drug manufacturing on a contract basis to life science companies, with the current lead product being an oral vaccine for cancer treatment. Drug Development and Drug Manufacturing Canada $5m Revenue generating
26 A revenue producing Diagnostics company aiming to accelerate pharma drug development and time to market by months and years, selling 50 unique assays to pharma in 2018. Drug Development and Drug Manufacturing USA $2.5m Revenue generating
27 A Biomed company that is developing a novel therapeutic for healing of gut tissue using a naturally occurring physiological peptide, targeting gastrointestinal disorders including Crohn's disease, ulcerative colitis and necrotizing enterocolitis. Gastroenterology USA $13m Preclinical
28 A Biotech company pioneering material development applications for metabolic health, its leading candidate is currently a first in class oral diabetes drug therapy which lowers blood sugar, body weight and blood lipids without systemic absorption. Gastroenterology Sweden $3.5m Phase 2
29 A Biotech company focused on developing a biologic drug, designed to treat celiac disease through breaking down gluten in the diet therefore making gluten fragment small enough to be non-immunogenic so patients can continue to eat gluten in their diet. Gastroenterology (Celiac Disease) USA $5-$8m Phase 2/3
30 A Biomed company developing safe and effective treatments for diabetes and fatty liver disease, whereby fat storing cells are turned into fat burning cells. Gastroenterology (Diabetes & Fatty Liver Disease) USA $17m Preclinical
31 A Biomed company developing small molecule therapeutics for non-alcoholic fatty liver disease and NASH with two leading drugs: IKKe/TBK1 inhibitors and Caspase 2 inhibitors, designed to address the early-stage fundamental mechanisms of the disease. Gastroenterology (Non-Alcoholic Fatty Liver Disease and NASH) USA $12m Phase 1
32 A Biotech company that provide patients with a gene testing toolkit so that DNA based lifestyle recommendations can be given and patients can better understand their food sensitivities and pet allergies. Genetic Testing USA $2m Revenue generating
33 A Biomed company targeting the process that drives sickle cell disease by developing an orally available long-term treatment that blocks P-selectin, site of sickle cell adhesion to vascular endothelium, in order to avert painful vaso-occlusive crises. Haematology USA $3.5m Phase 1/2
34 A Biotech company with four products designed to provide a remedy for specific problems, each the first of its kind, including: antimicrobial hospital laundry additive, disinfecting and protecting hand sanitizer, disposable antimicrobial surgical/procedure mask and reusable antimicrobial respirator mask. Infection Control USA $5m Multiple FDA approvals & CE mark obtained
35 A Biomed company regulating Natural Killer T (NKT) cells for therapeutic outcomes in diverse inflammatory conditions including liver disease (for example NASH) and autoimmunity (for example rheumatoid arthritis). Inflammatory Disease USA $20-$30m Phase 2
36 A niche R&D stage, virtual pharmaceutical company focused on the identification and development of challenging generic injectable products. Injectables USA $12m R&D stage
37 A Biomed company that is developing a searchable data library that links data from disparate locations and allows for data to be analysed in a single research environment, providing a searchable library of biosamples, genomic, patient phenotypic and medical data. Medical Data USA/UK $5m Launch phase
38 A Biomed company that is developing a library construction for small genome plasmids and gene constructs with applications including: microbiome screening, microbial whole genome sequencing, quality control of synthetic constructs and genotyping by sequencing. Medical Data USA $2m Completing FDA approval trials
39 A Medical device company acquiring technologies at early stages of commercialisation, creating a portfolio of devices currently building revenue with the first acquisition being a spinal pedicle screw system that allows the company to sell implants for entire lumbar spine procedures. Medical Device USA $12m Revenue generating
40 A Medical Software company producing software that improves MRI image quality, streamlines MRI workflow and shortens imaging exam time while providing now-accessible and valuable functional data. Medical Imaging USA $1.5m Preparing for clinical trials
41 A Medical Device company that is producing a video laryngoscope which is more convenient as only one hand is needed to manipulate the blade together with exceptional battery life and useful portability. Medical Imaging France $2.7m Commercial launch - June 2019
42 A Medical Device company that is developing advanced diagnostic 3D imaging technologies, the company's software immediately reconstructs and displays a full 3D model from 3D X-Ray technology that is easily rotated, filtered, sliced and has adjustable contrast for better patient and practitioner experience. Medical Imaging USA $3m Completing FDA approval trials
43 A Medical Device company that has produced a medical imaging endoscopy machine with software that has an Automatic Polyp Detection System (APDS), which is able to automatically identify polyps during a colonoscopy via a tracking algorithm, hence faster diagnosis of diseases such as colorectal cancer. Medical Imaging Israel $2m Preclinical
44 A Biomed company developing a process whereby all infection can be detected in one test, including every bacteria, virus, fungus and parasite, with quick and effective identification and results. Microbiology USA $2m Revenue generating
45 A Biomed company developing a point of care lateral flow assay, similar in form to a home pregnancy test, that determines the HIV status and recency of HIV infection, using a single blood droplet and working in 20 minutes with no specialised lab equipment. Microbiology (HIV) USA $5m Revenue generating
46 A Biotech company focused on modulation of gut microbiome with targeted pro/prebiotics towards health and disease for human applications such as treating chronic kidney disease and managing gout. Microbiome USA $10m Commercial stage
47 A Medical Device company that produces microneedle array devices, named "adminpen", allowing for more effective and painless injection of immunotherapies, vaccines, pharmaceutical drugs, and cosmetic agents. Microneedle array Medical Device USA $0.5-$4m Developed and launched for research use
48 A Pharmaceutical company developing a novel gene therapeutic that inhibits muscle wasting and promotes muscle growth, useful for conditions such as: cancer cachexia, heart failure, and muscular dystrophy etc. Musculoskeletal USA $2m Phase 1
49 A private, clinical stage gene therapy company focused on the development of a therapy to increase muscle strength and prevent muscle atrophy for debilitating muscle diseases. Musculoskeletal USA $15m Phase 1/2
50 A Biomed company developing a drug to treat muscular dystrophy, a disease for which no current definitive treatment exists, via a recombinant human protein Laminin-111. Musculoskeletal USA $25m Preclinical
51 A Biotech company developing a novel, first-in-class DAMA (delta agonist, mu antagonist) compound that targets specific subtypes of opioid receptors in order to treat the symptoms of Parkinson's disease. Neurodegenerative USA $650k Preclinical
52 A Biomed company designing a new highly effective therapy to be used in Parkinson's disease, an endogenous neuromodulator that will result in reduced dyskinesia allowing doctors to prescribe higher doses of Levodopa (the current treatment) and less side effects allowing Levodopa to be prescribed for more years. Neurodegenerative Spain $1.5m Preclinical
53 A Biomed company that is developing novel therapies for neuropsychiatry and neurovascular diseases including a drug intended to treat schizophrenia and bipolar disorder via antipsychotic properties. Neuropsychiatry and Neurovascular USA $20m Phase 2/3
54 A Pharmaceutical company developing an anti-cancer drug that kills cancer cells through 'autophagy'. Oncology Spain $5.7m Phase 2
55 A Biomed company producing 3D Bioprinters and Universal Cancer Bioink allowing for the first printed patient-derived tumour cells to live so that diagnosis and treatment can be effective to each individual patient. Oncology USA $6m Revenue generating
56 A Biotech company using an AI approach to dominate the personalised cancer diagnostics market with AI based gene expression analysis that can generate a complete set of diagnostics to decide if a patient needs further treatment to prevent recurrence of cancer. Oncology USA $10-$20m Clinical studies
57 A Biomed company with a novel innovative immunotherapy drug based on a new tumour antigen that is designed to treat cancers, currently including lung cancer, neuroendocrine tumours and thyroid cancers. Oncology France $5.7m Preclinical
58 A Biomed company developing drugs to treat cancer through inhibiting targets across pathways involved in the tumour evasion of the immune system. Oncology Netherlands $11m Preclinical
59 A Biopharmaceutical company focused on the development and commercialisation of oncology and oncology supportive care medicines including for severe oral mucositis in oropharyngeal cancer and an additional product designed to avoid the irreversible cardiotoxicity that has historically limited the chemotherapeutic potential of doxorubicin, among other drugs. Oncology USA $20m Phase 2/3
60 A Biomed company developing a Personal Discovery Process (PDP) where personalised cancer therapeutics are identified through analysis of patient's entire exome to capture the tumour network and screened against up to half a million FDA approved drugs. Oncology UK $2.5m Preclinical
61 A Biomed company focused on developing a targeted, non-invasive treatment that utilises targeted, ultra-low radio frequency energy in order to treat cancers, with current spotlight on applications in brain cancer. Oncology USA $15-$20m Near term revenue - Q2/2019 & CE Mark - Q3
62 A Biomed company using advanced biomarker-based cervical screening to replace cytology screening and HPV detection with greater clinical benefit and at lower costs, a '1 stop shop' on cervical cancer detection. Oncology USA $5.5m Lead secured - seeking co-investor
63 A Biomed company aiming to improve the quality of cancer care with products that address unmet needs in breast and pancreatic cancer diagnosis and treatment using specific target cells. Oncology USA $8m Clinical & Commercial
64 A Biotech company that has identified a unique biomarker for breast cancer that also functions as an excellent drug target for the development of therapies for breast cancer. Oncology USA $12m Preclinical
65 A Biomed company with a mission to improve cancer treatment with drugs and radiotherapy with a focus on radiation sensitiser drugs to cure cancer patients. Oncology USA $35m Phase 1
66 A Biomed company developing drugs to treat cancer therapy induced alopecia and radio-dermatitis and enhance radiotherapy and chemotherapy efficacy. Oncology China $5m Phase 2/3
67 A Biomed company developing a therapeutic candidate to treat metastatic diseases with the lead product being TTX-MC138 which eliminates metastasis by inhibiting microRNA-10B resulting in the death of metastatic tumour cells. Oncology USA $36m Phase 2
68 A Biomed company in its clinical stage with a cell imaging platform that is able to detect abnormal cell allowing for quicker diagnosis of cancer and hence early intervention, also developing a non-invasive sputum-based test that detects abnormalities which indicate lung cancer and lung dysplasia. Oncology USA $50m Clinical stage - $35m raised
69 A Biomed company using its proprietary biologic, alpha fetoprotein, to treat immunological patients (including those suffering from autoimmune problems such as myasthenia gravis) and oncological patients. Oncology and Immunology Canada $10m Phase 2
70 A Biomed company building compounds that bridge the gap between innate and adaptive immunity in order to re-target and kill cancer cells. Oncology and Immunology USA $2.5m Preclinical
71 A Biomed company rolling out the first and only dichoptic therapy for the treatment of amblyopia (lazy eye). Ophthalmology USA $10m Launch phase
72 A Biotech company developing a neuroprotective treatment for eye diseases or conditions whereby the blood supply to the eye is either reduced or blocked. Ophthalmology Australia $1.2m Preclinical
73 A Medical Software company creating a mobile software smartapp that can be used to enable non-specialists to detect invisible eye problems using a smartphone and hence diagnose diseases much quicker. Ophthalmology USA $2m FDA-registered & CE certified.
74 A Biomed company developing 2-iminobiotin as a novel injectable pharmaceutical product to reduce the deleterious effects of oxygen shortage in the brain, occurring in: cardiac arrest and brain asphyxia. Oxygen Supply to Brain Netherlands $22m Phase 2
75 A Biomed company that is developing a drug designed to treat neuropathic chronic pain via mechanisms of the voltage gated sodium channels, however only targeting the spinal cord without penetrating the brain, a problem that current drugs present. Pain Switzerland $5.7m Phase 1
76 A Medical Software company developing software that allows for better patient engagement with health providers and a system whereby patients are sent automated care plan instructions, educational materials and allowing for monitoring and real time communication between office visits. Patient Engagement Software USA $6.5-$7.5m Recurring revenue
77 A Medical Software company developing a platform that truly personalises health information for people diagnosed with serious/chronic illness and their caregivers via a software providing a personalised, AI-powered "GPS" to navigate any chronic illness. Patient Engagement Software Israel $6-7m Commercial stage
78 A Medical Software company producing a phone app that collects patient data, aggregates phenotype and genotype data, provides a personalised platform self-customisation for many conditions, provides simple access to genomics, allows data sharing and allows user data monetisation. Patient Engagement Software USA $3m Launch phase
79 A Biomed company focusing on developing a new generation of photosentizers or contract imaging agents capable to provide fluorescence imaging for MRI, PET etc. and also capable of providing the same compound tools for guidance surgery and cancer treatment with photodynamic therapy. Photosentizers for Contrast Imaging and Photodynamic Therapy USA $5m Phase 2
80 A Biomed company that is developing a drug designed to treat severe depression and severe bipolar depression with acute suicidal ideation, the first drug that will be able to treat depression in bipolar disorder as SSRIs are not used in patients suffering from bipolar disorder. Psychiatry USA $70m Phase 2/3
81 A Biomed company developing placenta derived biotherapeutics for in situ regenerative healing (of for example necrotizing enterocolitis and osteoarthritis among many others) using placental cytokines and growth factors. Regenerative Medicine and Cell Therapy USA $1.5m Preclinical
82 A Biomed company focused on the use of tissue-specific epithelial stem cells to create novel cellular therapies and diagnostics with the leading product being a tissue engineered skin substitute 'chassis' enabling autologous treatment of multiple skin disease indications. Regenerative Medicine and Cell Therapy USA $10-15m IND
83 A Biopharmaceutical company dedicated to the development and production of high quality natural substance drugs to manage sinusitis, inflammation of one or more of the paranasal sinuses. Respiratory Spain $5.7m Commercial stage
84 A Biomed company producing a nebulised non-systemic biologic drug for airway mucous normalisation in cystic fibrosis and bronchiectasis. Respiratory USA $8m Preclinical
85 A Biotech company developing a blood flow imaging system to be used in surgery, mainly bypass heart surgery, with actual blood flow speeds in vessels and surrounding tissue real-time visualisation. Surgery USA $5m Launch phase
86 A Biopharmaceutical company focused on producing locally applied drug treatments for common bladder disorders with the most advanced product targeting interstitial cystitis. Urology USA $1m Phase 2
87 A Biomed company producing vaccinations that mimic the body's own natural immune response process. Vaccination Canada $5m Between discovery / Ready for clinical development
88 A Regenerative Medicine company with two FDA approved products associated with wound care and sports medicine including a collagen matrix for chronic skin wounds and a rotator cuff muscle bioimplant for faster recovery and stronger repair of rotatory cuff damage. Wound Care and Sports Medicine USA $15m Commercial stage